Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
LONDON, UK – May 22, 2018 – Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today presented Phase 2a and pharmacokinetic data from two clinical trials evaluating its lead product candidate, RPL554, in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference (ATS 2018), in San Diego. Results from these trials were previously reported by Verona Pharma on September 7, 2017 and September 27, 2017, respectively.
RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 designed to have anti-inflammatory as well as bronchodilator properties, and is currently in development for the maintenance treatment of COPD and for the treatment of cystic fibrosis.
The poster, titled, “RPL554, A First-In-Class Dual PDE3/4 Inhibitor, Causes Rapid Additional Bronchodilation When Dosed with Tiotropium in COPD Patients,” provided a review of the positive data from Verona Pharma’s Phase 2a clinical trial, in which RPL554 was dosed in addition to tiotropium (Spiriva®), one of the most commonly used drugs to treat COPD. In summary, the data from this Phase 2a trial demonstrated significantly improved peak lung function when RPL554 was added to tiotropium in patients with moderate-to-severe COPD.
This was a double blind, placebo-controlled, three way cross-over trial in 30 subjects with COPD and included two different doses of RPL554, 1.5 mg and 6 mg, or placebo, dosed twice-daily for three days, in addition to tiotropium, a long-acting anti-muscarinic (LAMA) bronchodilator, dosed once-daily (ClinicalTrials.gov Identifier: NCT03028142). The primary outcome measures for the trial were peak forced expired volume in one second (FEV1) on the third day of dosing and the average FEV1 on the third day of dosing, representing measures of lung function and duration of effect. A number of secondary outcome measures were also recorded. Of note, the 6 mg dose of RPL554 achieved statistical significance, compared to placebo, on all primary and secondary outcome measures. The data confirmed dose dependency between the two RPL554 doses.
- Primary outcome measures: RPL554, compared to placebo, produced a statistically significant (1.5 mg, p=0.002; 6 mg, p<0.001) and a clinically meaningful (>100 ml) peak FEV1 on the third day of dosing (additional bronchodilation) when administered on top of the standard bronchodilator, tiotropium (Spiriva®). Average FEV1 on the third day of dosing (0 - 12 hours) of RPL554 when added on top of tiotropium was larger than that of tiotropium alone (1.5 mg, p=0.099; 6 mg, p<0.001).
- Secondary outcome measures: Both doses of RPL554 produced a statistically significant faster onset of action (1.5 mg, 4.2 min; 6 mg, 4.6 min) when added to tiotropium compared to tiotropium alone (37.6 min; p<0.001). The administration of RPL554 as an add-on treatment to tiotropium caused a marked reduction in Functional Residual Capacity (1.5 mg, p<0.01; 6 mg, p<0.05) and in Residual Volume (1.5 mg, p=0.07; 6 mg, p<0.01), both measures of trapped air in the lung, as compared to tiotropium alone. Suggesting that RPL554 treatment may reduce dyspnea, a major debilitating symptom of COPD.
- Both doses of RPL554 were well tolerated as add-on treatments to tiotropium: Adverse reactions were consistent with previous studies with RPL554 and tiotropium. No cardiovascular-related or gastrointestinal related adverse reactions were reported.
In addition, Verona Pharma presented data at ATS from its pharmacokinetic trial with RPL554 in a poster titled, “Low Oral Bioavailability of RPL554, a First-in-Class Dual PDE3/4 Inhibitor, Demonstrates that its Nebulized, Inhaled Formulation is Appropriate for Delivering Optimal Pulmonary Dose,” which showed that inhaled RPL554 is an appropriate form of administration for patients with COPD and other respiratory disorders.
This complete block two-way crossover trial evaluated a single dose of RPL554 in 12 healthy volunteers to determine the process of bodily absorption, distribution, metabolism and excretion of this novel therapy, including the swallowed portion of the nebulized dose. The trial was conducted under an Investigational New Drug application accepted by the U.S. Food and Drug Administration in June 2017.
With any inhaled or nebulized medication, a portion of the substance is deposited in the mouth and then swallowed by the patient. These results showed that in the study subjects, only 10.4 percent of the inhaled dose entered the bloodstream via the gastrointestinal tract. The low oral bioavailability of nebulized RPL554, as demonstrated in the study, is consistent with optimal inhaled delivery of medications for the treatment of COPD and asthma. Therefore, the results from this study confirmed that inhaled RPL554 is an appropriate form of administration for patients.
Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester, presented the RPL554 with tiotropium data at ATS and commented, “These encouraging data warrant further investigation of RPL554 to meet the urgent need for drugs with novel mechanisms of action that can be used in addition to current therapies, in order to provide further treatment of both COPD symptoms and exacerbations.” “These positive data are further evidence of RPL554’s promising therapeutic potential for the treatment of COPD patients, further supporting Verona’s ongoing clinical development program,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “We look forward to advancing development of this first-in-class treatment this year by initiating in the third quarter a Phase 2a clinical trial to evaluate RPL554 when dosed in addition to LAMA/LABA therapy or triple therapy, compared to placebo. We also plan this year to complete pre-clinical studies for RPL554 delivered as both pressurized metered dose inhaler and dry powder inhaler formulations, followed by clinical trials in healthy subjects or patients with COPD targeted to commence in the first quarter of 2019.”
In March 2018, the Company reported positive top-line results from a Phase 2b trial for the maintenance treatment of COPD. The study met its primary endpoint, with RPL554 producing a clinically and statistically significant improvement in FEV1 at four weeks in patients with moderate-to-severe COPD compared to placebo. Furthermore, the peak FEV1 was significantly improved at all time points over the four weeks of dosing. Secondary endpoints measuring 12 hour average FEV1, progressive improvement in COPD symptoms and Quality of Life were also met and support the potential clinical benefits of RPL554 for the treatment of COPD. RPL554 was well tolerated at all doses with an adverse event profile similar to placebo.